Perspective - Archives of Industrial Biotechnology (2023) Volume 7, Issue 3
Biopharmaceuticals of the Future: Industrial Biotechnology's Role in Advanced Medicines
Frank T Danile*
Department of Management, The Eli Broad Graduate School of Management, Michigan State University, East Lansing, USA
- Corresponding Author:
- Frank T Danile
Department of Management
The Eli Broad Graduate School of Management
Michigan State University, East Lansing, USA
Email id: firstname.lastname@example.org
Received: 24- May-2023, Manuscript No. AAAIB-23-109057; Editor assigned: 26- May -2023, PreQC No. AAAIB-23-109057 (PQ); Reviewed: 09- Jun -2023, QC No. AAAIB-23-109057; Revised: 13-Jun -2023, Manuscript No. AAAIB-23-109057 (R); Published: 20- Jun-2023, DOI:10.35841/aaaib-7.3.147
Citation: Daniel FT. Biopharmaceuticals of the future: Industrial biotechnology's role in advanced medicines. J Arch Ind Biot. 2023;7(3):147
In recent decades, the field of biopharmaceuticals has witnessed remarkable advancements, revolutionizing the way we treat various diseases and medical conditions. These ground breaking medicines, derived from living organisms, have proven to be highly effective and have shown great promise in addressing some of the most challenging health issues faced by humanity. Industrial biotechnology plays a pivotal role in the development and production of these advanced medicines, and its continued growth is expected to shape the future of healthcare. In this article, we will explore the role of industrial biotechnology in the evolution of biopharmaceuticals and the potential impact it holds for the future of medicine.
Biopharmaceuticals, also known as biologics, are a class of drugs produced through biotechnology processes, primarily utilizing living cells and microorganisms. Unlike traditional small-molecule drugs, which are chemically synthesized, biopharmaceuticals are large, complex molecules that are derived from living sources. This unique characteristic grants them a significant advantage in targeting specific disease pathways with high precision, resulting in improved therapeutic outcomes and fewer side effects for patients .
The rise of industrial biotechnology has been instrumental in the development and production of biopharmaceuticals.This multidisciplinary field combines biology, chemistry, genetics, and engineering principles to harness living organisms' capabilities to produce valuable products, including medicines.
Biopharmaceuticals are typically manufactured using cell culture technology, where living cells are cultivated in bioreactors to produce the desired therapeutic proteins. Industrial biotechnology has led to significant advancements in bioprocessing techniques, optimizing cell culture conditions, and increasing production yields. This has resulted in more cost-effective and scalable processes, making these life-saving medications more accessible to patients worldwide. Advances in gene editing technologies, such as CRISPR-Cas9, have opened up new avenues for personalized medicine. Industrial biotechnology plays a crucial role in applying gene editing techniques to modify cells' genetic makeup, tailoring treatments to individual patients' specific needs. This approach has shown immense promise in treating genetic disorders, cancer, and other diseases with a strong genetic component .
Monoclonal Antibodies (MABS)
Monoclonal Antibodies (MABS) are a prominent class of biopharmaceuticals that have demonstrated remarkable success in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Industrial biotechnology has enabled the large-scale production of MABS by manipulating living cells to secrete these specific antibodies. The development of hybridoma technology and recombinant DNA techniques paved the way for producing fully human monoclonal antibodies, reducing the risk of immune reactions and improving their therapeutic efficacy .
Vaccines have played a crucial role in eradicating and controlling infectious diseases globally. Industrial biotechnology has played a pivotal role in the development and manufacturing of biological vaccines. From traditional inactivated or attenuated vaccines to the more recent mRNAbased vaccines, biotechnological advancements have accelerated the vaccine development process, as demonstrated during the COVID-19 pandemic. This rapid response to emerging health threats showcases the potential of industrial biotechnology in shaping the future of preventive medicine .
Industrial biotechnology benefit
Industrial biotechnology has paved the way for the emergence of novel therapies that were once deemed science fiction. For instance, gene therapies and cell-based therapies offer potential cures for previously untreatable diseases. By harnessing the power of genetic engineering and cell manipulation, these therapies hold great promise in treating genetic disorders, neurodegenerative diseases, and even repairing damaged tissues.
Biopharmaceuticals often face challenges in terms of stability and targeted delivery. Industrial biotechnology is at the forefront of developing innovative drug delivery systems that ensure the safe transport and release of therapeutic molecules to the target site. This includes the development of nanoparticles, liposomes, and other nanotechnology-based carriers that can improve drug stability and enhance therapeutic outcomes.
With the expiration of patents on some first-generation biopharmaceuticals, industrial biotechnology has enabled the production of biosimilars- products that are highly similar to the original biologics. Biosimilars offer more affordable treatment options and increase market competition, benefiting patients and healthcare systems. Additionally, biobetters, which are improved versions of existing biopharmaceuticals, are being developed through industrial biotechnology, providing enhanced therapeutic profiles and patient outcomes.
Industrial biotechnology not only impacts the development of medicines but also contributes to the industry's overall sustainability. Bioprocessing techniques are often more environmentally friendly compared to traditional chemical synthesis methods, reducing waste and energy consumption. Additionally, the use of renewable resources and bio-based feedstocks in biopharmaceutical production can further enhance the industry's environmental footprint.
Future of biopharmaceuticals
The future of biopharmaceuticals holds great promise, and industrial biotechnology will undoubtedly play a central role in shaping this promising landscape. As technologies continue to evolve, we can expect more innovative treatments, personalized medicines, and breakthrough therapies that will revolutionize healthcare and improve patients' quality of life.
However, with all the potential benefits, there are also challenges that need to be addressed. The complexity of biopharmaceutical production requires stringent quality control measures to ensure product safety and efficacy. Regulatory agencies worldwide play a crucial role in overseeing the development, manufacturing, and approval of these advanced medicines to protect patients' well-being .
Moreover, as the industry continues to grow, it is essential to address issues related to affordability and accessibility. Biopharmaceuticals, particularly novel therapies, can be costly, limiting access for some patients. Collaborations between governments, industry stakeholders, and healthcare providers are essential to finding sustainable solutions that make these transformative medicines accessible to all who need them.
In conclusion, the evolution of biopharmaceuticals driven by industrial biotechnology represents a remarkable milestone in medicine's history. The ongoing advancements in bioprocessing, gene editing, and personalized medicine have opened up new possibilities for treating diseases that were once considered incurable. As we move forward, a focus on ethical, affordable, and equitable distribution of these advanced medicines will ensure that the benefits of biopharmaceuticals of the future are realized by all, improving global health and well-being in the years to come.
- Johnson IS. The trials and tribulations of producing the first genetically engineered drug. Nat Rev Drug Discov. 2003;2(9):747-51.
- Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Human Gene Therapy. 2005;16(9):1016-27.
- Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131–labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol.2005;23(7):1538-47.
- Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646-54.
- Bao GQ, Li Y, Ma QJ, et al. Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol 2005;4(12):1374-80.